✦ LIBER ✦

Firm Value and Geographic Competitive Advantage: Evidence from the U.S. Pharmaceutical Industry*

✍ Scribed by Boasson, Vigdis; Boasson, Emil; MacPherson, Alan; Shin, Hyun‐Han

Book ID: 123881088
Publisher: University of Chicago Press
Year: 2005
Tongue: English
Weight: 605 KB
Volume: 78
Category: Article
ISSN: 0021-9398
DOI: 10.1086/497038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CEO compensation and firm competitive be

CEO compensation and firm competitive behavior: Empirical evidence from the U.S. pharmaceutical industry

✍ Evan H. Offstein; Devi R. Gnyawali 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 234 KB

The Dominant-Firm Advantage in Multiprod

The Dominant-Firm Advantage in Multiproduct Industries: Evidence from the U. S. Airlines

✍ Severin Borenstein 📂 Article 📅 1991 🏛 MIT Press 🌐 English ⚖ 559 KB

COHERENCE OF THE KNOWLEDGE BASE AND THE

COHERENCE OF THE KNOWLEDGE BASE AND THE FIRM'S INNOVATIVE PERFORMANCE: EVIDENCE FROM THE U.S. PHARMACEUTICAL INDUSTRY

✍ Lionel Nesta; Pier Paolo Saviotti 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Patents and market value in the U.S. pha

Patents and market value in the U.S. pharmaceutical industry: new evidence from panel threshold regression

✍ Yu-Shan Chen, Chun-Yu Shih, Ching-Hsun Chang 📂 Article 📅 2013 🏛 Springer Netherlands 🌐 English ⚖ 496 KB

Strategic alliances for competitive adva

Strategic alliances for competitive advantage: evidence from Israel's hospitality and tourism industry

✍ John F. Preble; Arie Reichel; Richard C. Hoffman 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 121 KB

An empirical analysis of sustained advan

An empirical analysis of sustained advantage in the U.S. pharmaceutical industry: impact of firm resources and capabilities

✍ Poh-Lin Yeoh; Kendall Roth 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 3 views

The authors test a model of the relationships among firm resources, firm capabilities, and sustained competitive advantage between 1971 and 1989. Sustained comparative advantage was captured by two variables: therapeutic differentiation and global NCEs. The results show that R&D and salesforce expen